DR Congo’s 17th Ebola outbreak has pushed the death toll past 500. The epidemic is driven by the Bundibugyo strain, and there is no existing vaccine or approved treatment for it.
2:41 PMAl Jazeera8 stories from 5 sources
Ebola’s toll rises as treatment reaches emergency use
Day’s Recap
Supporting Articles
Island Pharmaceuticals said its experimental antiviral galidesivir received regulatory and ethics approvals for emergency use in Uganda to treat patients infected with the Bundibugyo strain of Ebola. The company’s shares rose as much as 47% following the announcement.
8:52 PMBloomberg MarketsVertex will pay $10 billion to acquire Crinetics Pharmaceuticals, adding Crinetics' drug for a rare endocrine disorder to its portfolio. The deal extends a wave of large-cap biotech acquisitions aimed at buying late-stage or de-risked assets.
4:52 PMStat NewsNovartis agreed to acquire a UK cancer-focused biotech for $1.5bn. The target was formed in 2019 as a spinout from Imperial College and the Francis Crick Institute.
4:02 AMFinancial Times2:41 PMAl Jazeera
Ebola death toll in DR Congo surpasses 500
Summary
DR Congo’s 17th Ebola outbreak has pushed the death toll past 500. The epidemic is driven by the Bundibugyo strain, and there is no existing vaccine or approved treatment for it.
Why it matters
A high fatality outbreak without a vaccine increases the odds of prolonged transmission and destabilizes already fragile health infrastructure.
8:52 PMBloomberg Markets
Island Pharma Jumps After Emergency-Use Approval for Ebola Drug
Summary
Island Pharmaceuticals said its experimental antiviral galidesivir received regulatory and ethics approvals for emergency use in Uganda to treat patients infected with the Bundibugyo strain of Ebola. The company’s shares rose as much as 47% following the announcement.
Why it matters
Emergency-use clearance can turn an early-stage antiviral into an on-the-ground option during an outbreak, with fast-moving implications for patients, procurement, and the drug’s commercial and clinical trajectory.
4:52 PMStat News
STAT+: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms
Summary
Vertex will pay $10 billion to acquire Crinetics Pharmaceuticals, adding Crinetics' drug for a rare endocrine disorder to its portfolio. The deal extends a wave of large-cap biotech acquisitions aimed at buying late-stage or de-risked assets.
Why it matters
A $10 billion biotech takeout reinforces a higher clearing price for late-stage rare-disease assets and signals more consolidation ahead.
4:02 AMFinancial Times
Novartis to buy UK biotech in $1.5bn deal
Summary
Novartis agreed to acquire a UK cancer-focused biotech for $1.5bn. The target was formed in 2019 as a spinout from Imperial College and the Francis Crick Institute.
Why it matters
It signals sustained strategic demand for oncology pipelines and validates UK academic spinouts as acquisition targets at scale.
Other Developments
A curated list of other prominent stories from this day.
New federal data show many states experienced steep declines in Affordable Care Act marketplace enrollment over the past year. The drops varied by state but collectively indicate fewer people are covered through ACA plans than a year earlier.
3:58 PMStat NewsA new study finds apolipoprotein B (apoB) testing outperforms standard LDL cholesterol for identifying people who need more intensive lipid-lowering treatment. The researchers conclude broader apoB use could avert more heart attacks and strokes while staying cost-effective for the U.S. healthcare system.
5:03 AMScienceDailyJerome Adams argues the FDA should adopt a structured, clinician guided regulatory framework for the booming market of popular peptides. The goal is to separate legitimate therapeutic use from unproven, loosely marketed products while preserving access under medical oversight.
4:30 AMStat NewsRepublican lawmakers are urging the Trump FDA to prioritize diversity in clinical trials, framing it as a scientific and safety requirement rather than a DEI initiative. They argue that drugs and devices need evidence across populations to ensure performance and dosing are valid in real world use.
4:30 AMStat News3:58 PMStat News
Obamacare rolls shrank dramatically in many states over the past year, new federal data shows
Summary
New federal data show many states experienced steep declines in Affordable Care Act marketplace enrollment over the past year. The drops varied by state but collectively indicate fewer people are covered through ACA plans than a year earlier.
Why it matters
Fewer ACA enrollees can raise costs and reduce access, with immediate consequences for consumers, insurers, and state health budgets.
5:03 AMScienceDaily
Millions may be getting the wrong cholesterol test
Summary
A new study finds apolipoprotein B (apoB) testing outperforms standard LDL cholesterol for identifying people who need more intensive lipid-lowering treatment. The researchers conclude broader apoB use could avert more heart attacks and strokes while staying cost-effective for the U.S. healthcare system.
Why it matters
Switching the default cholesterol test could change who gets statins and other therapies, with population-level implications for preventable cardiovascular events and healthcare spending.
4:30 AMStat News
Opinion: The smart way to regulate the peptide boom
Summary
Jerome Adams argues the FDA should adopt a structured, clinician guided regulatory framework for the booming market of popular peptides. The goal is to separate legitimate therapeutic use from unproven, loosely marketed products while preserving access under medical oversight.
Why it matters
A workable peptide framework could reduce harm and fraud without shutting down patient access or innovation.
4:30 AMStat News
STAT+: GOP lawmakers push Trump’s FDA to make sure clinical trials are diverse
Summary
Republican lawmakers are urging the Trump FDA to prioritize diversity in clinical trials, framing it as a scientific and safety requirement rather than a DEI initiative. They argue that drugs and devices need evidence across populations to ensure performance and dosing are valid in real world use.
Why it matters
If the FDA tightens expectations, trial design and approval risk will increasingly hinge on whether evidence reflects the patients who will use the product.
Make it yours
Build Your First Pass.
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!